An interventional study of HPV Self-collection in the ED in Cervical Cancer Screening and Human Papilloma Virus, sponsored by Rutgers, The State University of New Jersey. Recruiting at 2 sites in United States. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Papilloma with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Papilloma · United States.
Among the 51 studies in Papilloma with a site in United States, this one is the 24th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 50th registered.
89 studies on the registry are indexed under Papilloma; 20 are open to participants now.
Browse Papilloma studies →9 of the 51 studies in Papilloma with a site in United States are open now. Recruiting first, the newest first:
Daré Bioscience, Inc. · Sites in United States
Ages 22–50 · Women only
Mel Mont Medical · Sites in United States
Ages 25–65 · Women only · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 9–17
Case Comprehensive Cancer Center · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18–70 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Papilloma studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 30 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 4 3
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 118 across 65 interventional studies indexed under Papilloma.
Median enrollment 155 across the 39 interventional studies, 155 across the 12 observational. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 51 have an industry lead sponsor. The 10 most frequent:
Rutgers, The State University of New Jersey is the lead sponsor of 507 studies on the registry; 132 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
Rutgers, The State University of New Jersey has 1 study filed under Papilloma — fewer than ten, so there is no comparison to draw.
7 of the studies in Papilloma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07758140Mel Mont MedicalComparative Self-collection for Cervical Cancer Screening Pivotal Study | 2026-12 |
| NCT07060261Case Comprehensive Cancer CenterPre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma | 2026-12 |
| NCT06624839University of Maryland, BaltimoreEvaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV | 2027-01 |
| NCT06831383University of California, Los AngelesThe STOP-HPV Scale Up Study | 2027-04-19 |
| NCT07657104Rutgers, The State University of New JerseyDeveloping and Implementing HPV SCREENED | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 51 studies in Papilloma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED). Eligible participants will receive education and an HPV self-sampling kit to complete in the ED. Individuals with HPV-positive results will be guided to follow-up care at a local clinic.
The proposed study will implement HPV self-sampling as primary cervical screening for under-screened ED patients. The long-term goal is to increase access to cervical screening for women who may not routinely use primary care and thus face increased risk of cervical cancer. This pilot feasibility trial will implement HPV self-sampling kit distribution and navigation to follow-up care in the ED. The investigators hypothesize that ED-based in-person distribution and same-day return of HPV self-sampling kits will alleviate issues of prior mailed HPV self-sampling trials by reducing participant burden. Women (30-65 years with non-critically ill presentations) who present to the ED and are overdue for cervical screening will receive 1) cervical cancer screening education and 2) a HPV self-sampling kit where they return the kit immediately after self-sampling in the ED. ScreenNJ will navigate participants with HPV-positive results to follow-up care and management according to current standard guidelines at local clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A single-arm pilot trial of HPV self-sampling among under-screened women in the ED
Behavioral: HPV Self-collection in the ED
Participants will be asked to collect a vaginal sample for HPV screening.
Completion of ED-Based HPV Self-Sampling
Evaluate the proportion of eligible participants who complete HPV self-sampling during the emergency department visit.
Time frame: Day 1
HPV Self Sampling Acceptability
Acceptability of Intervention Measure (AIM) scale (Weiner et al., 2017). Scale values range from 1 to 5, where higher is more acceptable.
Time frame: After results notification, an average of 1 week
HPV Self Sampling Feasibility
Feasibility of Intervention Measure (FIM) scale (Weiner et al., 2017). Scale values range from 1 to 5, where higher is more feasible.
Time frame: After results notification, an average of 1 week
Screening Completion
Proportion of HPV+ women who complete follow-up screening
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.
Of 28 interventional studies with no phase under Papilloma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 8 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey →